Developer of scientific data management software designed to enhance workplace collaboration. Acquired by PerkinElmer (NYS: PKI) in March 2011.

Clearside Biomedical is a biopharmaceutical company focused on revolutionizing treatment for sight-threatening back-of-the-eye diseases. IPO in June, 2016 (NASDAQ:CLSD).

Clinipace is a clinical research organization whose services are enhanced by a proprietary on-demand software platform and clinical research services. Acquired by dMed in April 2021.

Developer of a system to enhance embolic cerebral protection. Acquired by Edwards Lifesciences (NYSE: EW) in March 2011.

Entegrion develops point-of-care hemostasis solutions centered on its Viscoelastic Coagulation Monitor (VCM)

GeneCentric’s mission is to address the urgent unmet need in precision oncology for better biomarkers and to bring these biomarkers to liquid biopsies.

HistoSonics, Inc. is pioneering a novel, non-invasive therapeutic platform based on histotripsy. Acquired by Bezos Expeditions, Wellington K5 Global 2025

The Company’s lead product candidate, PB2452, is a novel reversal agent for the antiplatelet drug ticagrelor. IPO in October, 2018 (NASDAQ:PHAS)

Viamet Pharmaceuticals is a biotechnology company. Acquired by NovaQuest Capital Management in January 2018.
